NDAORALCAPSULEPriority Review
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
15
Mechanism of Action
Glucosylceramide Synthase Inhibitors
Pharmacologic Class:
Glucosylceramide Synthase Inhibitor
Clinical Trials (5)
Eliglustat on Gaucher Disease Type IIIB
Started Apr 2018
4 enrolled
Gaucher Disease, Type III
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3
Started Apr 2018
57 enrolled
Gaucher's Disease Type IGaucher's Disease Type III
A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers
Started Jan 2018
18 enrolled
Gaucher's Disease
Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies
Started Oct 2015
31 enrolled
Gaucher Disease
A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
Started Sep 2015
24 enrolled
Gaucher Disease
Loss of Exclusivity
LOE Date
Dec 13, 2038
155 months away
Patent Expiry
Dec 13, 2038